Rafferty Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Rafferty Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$131K	Buy	15,443 +271	+2%	+$2.58K	﹤0.01%	1045
2025 Q4	$184K	Sell	15,172 -1,399	-8%	-$17K	﹤0.01%	1115
2025 Q3	$194K	Buy	16,571 +3,158	+24%	+$37.8K	﹤0.01%	1078
2025 Q2	$124K	Buy	13,413 +2,343	+21%	+$18.3K	﹤0.01%	1064
2025 Q1	$81.1K	Sell	11,070 -4,152	-27%	-$31.9K	﹤0.01%	1050
2024 Q4	$130K	Sell	15,222 -3,209	-17%	-$31.3K	﹤0.01%	1117
2024 Q3	$160K	Sell	18,431 -17,289	-48%	-$143K	﹤0.01%	1117
2024 Q2	$244K	Buy	+35,720	New	+$220K	﹤0.01%	1093
2023 Q4	–	Sell	-11,837	Closed	-$37.2K	–	1091
2023 Q3	$37.2K	Buy	+11,837	New	+$48.4K	﹤0.01%	1070
2022 Q1	–	Sell	-20,022	Closed	-$140K	–	1296
2021 Q4	$140K	Buy	20,022 +3,988	+25%	+$31K	﹤0.01%	1243
2021 Q3	$160K	Buy	16,034 +3,171	+25%	+$35.6K	﹤0.01%	1200
2021 Q2	$182K	Buy	+12,863	New	+$196K	﹤0.01%	1237

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Rafferty Asset Management's OCUL Position: Q1 2026 in Review

Rafferty Asset Management increased its Ocular Therapeutix (OCUL) stake by 1.8% in Q1 2026, buying an estimated $2.58K and bringing the position to 15,443 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1045.

Rafferty Asset Management first reported a position in OCUL in Q2 2021 and has held it in 12 quarters since. The position peaked at $244K in Q2 2024. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Rafferty Asset Management held 15,443 shares of Ocular Therapeutix worth $131K as of Q1 2026.
Rafferty Asset Management bought 271 Ocular Therapeutix shares in Q1 2026, an estimated $2.58K.
Ocular Therapeutix made up ﹤0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #1045 holding.
Rafferty Asset Management first reported a position in Ocular Therapeutix in Q2 2021 and has held it in 12 quarters since.
Rafferty Asset Management's Ocular Therapeutix position peaked at $244K in Q2 2024.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.